Eledon Pharmaceuticals, Inc. (ELDN) Discusses Phase II BESTOW Trial Results and Advances in Transplantation Immunosuppression Transcript

Operator

Good morning, ladies and gentlemen, and welcome to the Eledon Pharmaceuticals Phase II BESTOW Results Conference Call. [Operator Instructions] This call is being recorded on Friday, November 7, 2025.

And I would now like to turn the conference over to Dr. David-Alexander Gros. Thank you. Please go ahead.

David-Alexandre Gros
CEO & Non Independent Director

Thank you, operator, and good morning, everyone, and thank you for joining us on our call to review Eledon’s Phase II BESTOW data that we presented last night. I’m — this is David-Alexander Gros, I’m the CEO of Eledon, and I’m joined here today by my team with Steve Perrin, our President and Chief Scientific Officer; Paul Little, our Chief Financial Officer; Elie Katz, our Chief Medical Officer; Dave Hovland, our Chief Regulatory Officer. And we’re also happy to be joined today by Dr. Andrew Adams, who presented the data last night at ASN. He is Professor and Chief of the Transplantation Division at the University of Minnesota.

Moving on to the forward-looking statement slide. We will be making forward-looking statements, so please review this slide carefully. Moving to Slide 3. We are developing tegoprubart principally